201 E. FIFTH STREET, CINCINNATI, OH
Announces 1-for-10 Reverse Stock Split
Reports Q1 2026 Progress at Proteomedix, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
Onconetix, Inc. Holds Special Meeting; Approves Reverse Stock Split Proposal
Director Resignations - Andrew Oakley and Thomas Meier Step Down
Amended material disclosure
David White Appointed Chief Executive Officer of Onconetix, Inc.
To Acquire LLC, USA-based, AI-Powered Humanoid Robotics Company
Onconetix, Inc. Holds Special Meeting; Reverse Stock Split Proposal Voted
Q1
FY 2025
Q3
Q2
FY 2024
Notice of Late Filing for Annual Report
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Definitive Proxy Statement
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to Registration Statement
Submission Upload
Correspondence